

AUG. 21. 2007 12:49PM

NOVARTIS C. I. P. (973) 781-8064

NO. 8148 P. 1

Gregory D. Ferraro
Senior Patent Attorney
Metabolic & Cardiovascular
Disease (MCD)

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover NJ 07936-1080



Tel (862) 778-7831
Fax (973) 781-8064
Internet: gregory.ferraro
@novartis.com

Fax

RECEIVED
CENTRAL FAX CENTER
AUG 21 2007

Attention Office of Patent & Legal Administration
Patent & Trademark Office
Alexandria, VA

Fax no. (571)273-8300
Number of pages 3 including cover page

Date August 21, 2007

Concerning Case 33529-US-PCT - Application No. 10/580,295

Enclosed is a "Letter to Correct a Publication Application" for the above-mentioned application.
Thank you for your help in this matter.

Very truly yours,

A handwritten signature in black ink, appearing to read "Greg Ferraro".

Gregory D. Ferraro

GDF:

CONFIDENTIALITY NOTICE

THIS FAX CONTAINS CONFIDENTIAL INFORMATION WHICH MAY BE PRIVILEGED AND IS INTENDED SOLELY FOR THE USE OF THE ABOVE-NAMED RECIPIENT(S). IT MAY BE EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT AN INTENDED RECIPIENT OR PERSON RESPONSIBLE FOR DELIVERY OF THIS FAX TO AN INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS FAX IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISCLOSURE, COPYING OR OTHER USE OF THIS FAX OR ITS CONTENTS IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FAX IN ERROR, PLEASE NOTIFY THE SENDER IMMEDIATELY BY TELEPHONE AT ONE OF THE PHONE NUMBERS SET FORTH ABOVE AND DESTROY THIS FAX IMMEDIATELY.

AUG. 21. 2007 12:49PM

NOVARTIS C. I. P. (973) 781-8064

NO. 8148 P. 2

CASE 33529-US-PCT

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Dolores DeCarmine
Type or print name

Dolores DeCarmine
Signature

8/21/2007
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

SELLNER ET AL.

APPLICATION NO: 10/580,295

FILED: MAY 23, 2006

FOR: DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-ALKANOIC
ACID AMIDES AND USE AS RENIN INHIBITORS

RECEIVED
CENTRAL FAX CENTER
AUG 21 2007

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

LETTER TO CORRECT A PUBLICATION APPLICATION

Sir:

Upon review of the instant Publication No. US-2007-0142475-A1, Applicants noted that a Patent Office error appears on page 17 of the publication. The error in claim 6, line 11 should read: "butyric acid (1S, 2S, 4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-not "butyric acid
(1S,2S,4S,4S)-amino-1-[(S)-2-(2-carbamoyl-2-not and the location of the support is on page 35,
line 7, of claim 6 of the specification (a copy is attached herewith).

Please correct this error.

Respectfully submitted,

Gregory D. Ferraro

Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7831
GDF:dd


Date: August 21, 2007

*Case 33529-U S-PCT
application no. 10/580,295*

WO 2005/054177

PCT/EP2004/013589

- 35 -



(I B),

or a pharmaceutically acceptable salt thereof, wherein R⁹ is C₁-C₄-alkanoyl or a group of the formula -COCHR¹⁴NH₂ wherein R¹⁴ is C₁-C₄-alkyl, such as isopropyl or isobutyl, or phenyl-C₁-C₂-alkyl, such as benzyl.

6. A compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof selected from the group consisting of acetic acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester; propionic acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester; butyric acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester; isobutyric acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester; 2,2-dimethyl-propionic acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester; (S)-2-amino-3-methyl-butyric acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl Ester; (S)-2-amino-4-methyl-pentanoic acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester; and (S)-2-amino-3-phenyl-propionic acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester.